Marketing is the weakness for Aussie bio stocks which want to have market share in US, my other holding TD1 has the same problem as ANP, great product, equal or greater compared to their US counterpart(s), but does not have the fund and resources to open market in US, have to team up with US company and sell themselves short…… but even so is great, the first step of a long journey years to come
Ann: Positive feedback received on Paediatric Investigation Plan, page-56
-
- There are more pages in this discussion • 166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $21.40K | 203.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 215964 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 341886 | 4 |
View Market Depth
| Last trade - 10.06am 07/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |